Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Daratumumab Or Darzalex Market Forecast: What Market Value Is Expected By 2030?
The market for daratumumab, also known as Darzalex, has experienced substantial expansion in recent times. Projected to rise from $5618.3 million in 2025 to $6189.36 million in 2026, this growth reflects a compound annual growth rate (CAGR) of 10.2%. Historical growth drivers include its approval for treating multiple myeloma, impressive clinical results through CD38 targeting, a scarcity of options for relapsed disease, widespread adoption by oncology centers, and improvements in patient survival rates.
The market for daratumumab, also known as Darzalex, is projected to experience robust expansion in the coming years, reaching an estimated $9,024.5 million by 2030. This represents a compound annual growth rate (CAGR) of 9.9%. Growth during this forecast period is driven by several key factors: the broadening of combination treatment approaches, an increasing incidence of multiple myeloma, heightened investment in oncology research, the discovery of new therapeutic indications, and better access programs for patients. Noteworthy trends shaping the forecast period include the escalating use of daratumumab for multiple myeloma, its frequent incorporation alongside other cancer medications, its progression into earlier stages of treatment, the administration of monoclonal antibody therapies in hospital settings, and its wider application in treating hematologic cancers.
Download A Free Sample Report For Comprehensive Market Insights:
Daratumumab Or Darzalex Market Demand Drivers Creating New Revenue Opportunities
The increasing prevalence of bone marrow cancer is anticipated to boost the expansion of the daratumumab or darzalex market in the coming years. Bone marrow cancer encompasses malignancies that originate in the bone marrow, including multiple myeloma and leukemia, where abnormal blood cell production interferes with normal bodily functions. This growing incidence is linked to factors such as an aging population, enhanced detection techniques, and contributions from environmental exposures, lifestyle habits, and genetic predispositions. Daratumumab (Darzalex) is used to manage multiple myeloma, a form of bone marrow cancer, by specifically targeting and eliminating abnormal plasma cells within the bone marrow. For example, in January 2025, the American Cancer Society, a nonprofit organization based in the US, projected that approximately 3,770 new cases of primary bone and joint cancer (2,150 in males and 1,620 in females) and about 2,190 deaths (1,240 in males and 950 in females) would occur in 2025. Consequently, the rising frequency of bone marrow cancer is fueling the growth of the daratumumab or darzalex market.
The growing uptake of biologics and targeted therapies is forecasted to drive the daratumumab or darzalex market forward in the future. Targeted therapies involve medical treatments employing drugs or other agents to accurately identify and attack specific molecules crucial for cancer cell growth and survival. The increased use of biologics and targeted therapies is being spurred by the higher incidence of chronic conditions and progress in precision medicine, facilitating more customized and effective treatments. Daratumumab plays a role in targeted therapies through its targeted effect on CD38, a protein that is abundantly present on the surface of malignant plasma cells in multiple myeloma. As reported by the Personalized Medicine Coalition, a US nonprofit, in February 2024, the FDA approved 16 new personalized treatments for rare diseases in 2023, a notable rise from the six approvals in 2022. Thus, the increasing adoption of biologics and targeted therapies is propelling the growth of the daratumumab or darzalex market.
Daratumumab Or Darzalex Market Segmentation: How Is The Market Structured Across Key Categories?
The daratumumab or darzalex market covered in this report is segmented –
1) By Drug Type: 100Mg Injection, 400Mg Injection
2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels
3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications
Daratumumab Or Darzalex Market Trends Driving Strategic Industry Expansion
Leading players in the daratumumab, or Darzalex, space are prioritizing a paradigm shift in oncology care toward early therapeutic intervention, leveraging combination therapies to boost effectiveness against multiple myeloma and various cancers. These combination approaches involve blending two or more agents possessing distinct mechanisms of action, which can work synergistically to heighten efficacy, curb drug resistance, and enhance patient prognoses, all while possibly lowering adverse effects when compared to single-agent regimens. A notable example occurred in July 2024, when Johnson & Johnson, a pharmaceutical giant headquartered in the United States, secured U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), paired with bortezomib, lenalidomide, and dexamethasone (D-VRd), as induction and consolidation therapy for individuals newly diagnosed with multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT). This approval introduces a quadruplet therapy option at the start of treatment, which may lead to better patient results.
Daratumumab Or Darzalex Market Competitive Landscape And Leading Companies
Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.
Access The Complete Daratumumab Or Darzalex Market Report:
Daratumumab Or Darzalex Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model